A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs

Respiratory Care

Volumn 59, Issue 9, 2014, Pages 1353-1359

  Prescott, William A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Aminoglycoside; Cystic fibrosis; Extended interval dosing

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ARTICLE; AUDIOMETRY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG MONITORING; DRUG SAFETY; HEALTH CARE SURVEY; HEALTH PROGRAM; HUMAN; LUNG FIBROSIS; NEPHROTOXICITY; OTOTOXICITY; PRACTICE GUIDELINE; QUESTIONNAIRE; URINALYSIS; VESTIBULAR DISORDER; ADULT; BLOOD; CLINICAL PRACTICE; DISEASE COURSE; DRUG ADMINISTRATION; MIDDLE AGED; TRENDS; UNITED STATES;

ADULT; AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; GENTAMICINS; HEALTH CARE SURVEYS; HUMANS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; TOBRAMYCIN; UNITED STATES;

EID: 84928178146     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02980     Document Type: Article

References (20)

1. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312(7027): 338-345.
2. Chuck SK, Raber SR, Rodvold KA, Areff D. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000; 30(3): 433-439.
3. Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacotherapy 1995; 15(2): 201-209.
4. Phillips JA, Bell SC. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Intern Med J 2001; 31 (1): 23-26.
5. Tan KH, Hyman-Tylor P, Mulheran M, Knox A, Smyth A. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers. Pediatr Pulmonol 2002: 33(2): 165.
6. Cheong J, Jacklin A, Hodson M. The influence of the TOPIC study on the prescribing guidelines of aminoglycosides in cystic fibrosis units. Pediatr Pulmonol 2008; 43(S31): 363.
7. Condren M, Luedtke SA. Prescribing patterns for extended interval aminoglycoside dosing in pediatric patients. J Pediatr Pharmacol Ther 2001; 6: 385-391.
8. Van Meter DJ, Corriveau M, Ahern JW, Lahiri T. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44(4): 325-329.
9. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180(9): 802-808.
10. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006; 58(4): 822-829.
11. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol 2001; 31 (5): 367-376.
12. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentami-cin, netilmicin, and tobramycin. J Infect Dis 1983; 147(5): 918-932.
13. Riethmueller J, Franke P, Schroeter TW, Claass A, Busch A, Ziebach R, et al. Optimized intravenous antibiotic treatment with Ceftazidime (thrice daily vs. continuous) and tobramycin (thrice vs. once daily) in CF patients. Abstracts of the 24th European Cystic Fibrosis Conference, June 6-9, 2001, Vienna, Austria: P192.
14. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stable-forth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365(9459): 573-578.
15. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2010; (1): CD002009.
16. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998; 78(6): 536-539.
17. Vic P, Ategbo S, Turck D, Husson MO, Tassin E, Loeuille GA, et al. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996; 155(11): 948-953.
18. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002; 19(2): 303-309.
19. Prescott WA. National Survey of Extended-interval Aminoglycoside Dosing in Pediatric Cystic Fibrosis Pulmonary Exacerbations. J Pediatr Pharmacol Ther 2011; 16(4): 262-269.
20. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006; 42(10): 601-605.